Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management

Asli Bilgic MD, Salih Ozcobanoglu MD, Burcin Cansu Bozca MD, Erkan Alpsoy MD, MPhil

Akeniz University School of Medicine, Department of Dermatology and Venereology, Antalya, Turkey

A B S T R A C T

Livedoid vasculopathy (LV) is a rare, chronic, and occlusive disease of the veins supplying the upper parts of the skin. The pathogenesis of the disease is not precisely understood, and its attacks are often unpredictable but tend to worsen during the summer. LV affects women more often. This increased risk for LV in women might be related to sex-specific physiological conditions, such as pregnancy, or a higher incidence of LV-associated conditions, such as connective tissue diseases, hypercoagulable states, and venous stasis in women. The typical clinical appearance of LV consists of three main findings: livedo racemose, atrophic blanche, and skin ulcers. The purpose of this comprehensive review was to analyze LV in all aspects and mainly focus on early diagnosis for successful clinical management with a holistic and multidisciplinary approach. A detailed history, dermatological examination, and laboratory testing are essential for a diagnosis of LV. When LV is clinically suspected, a skin biopsy should be taken to confirm the diagnosis. Another critical step is to investigate the underlying associated conditions, such as connective tissue diseases, hypercoagulable states, thrombophilia, and malignancy. Unfortunately, no associated conditions can be detected in approximately 20% of all cases (idiopathic LV) despite all efforts. The diagnosis of the disease is delayed in most patients. Thus, irreversible, permanent scars appear. Early and appropriate treatment reduces pain and prevents the development of scars and other complications. Antiplatelet drugs and anticoagulants can be preferred as the first-line treatments along with general supportive measures. Other therapeutic options might be considered in unresponsive cases. Preference for refractory cases is based on availability, clinical experience, and patient-related factors (comorbidities, age, sex, and compliance). These include anabolic steroids, intravenous immunoglobulin, hyperbaric oxygen therapy, psoralen-ultraviolet A, vasodilators, fibrinolitics, immunomodulators, and immunosuppressives.

© 2021 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Contents

Introduction ......................................................................................................................... 589
Epidemiology ...................................................................................................................... 589
Pathogenesis ..................................................................................................................... 590
Histopathology .................................................................................................................. 590
Genetics ............................................................................................................................ 592
Clinical features ............................................................................................................... 592
Diagnosis and differential diagnosis ............................................................................... 593
Laboratory testing ............................................................................................................. 593
Treatment ......................................................................................................................... 596
Conclusion ....................................................................................................................... 597
Conflicts of interest ......................................................................................................... 597
Funding ............................................................................................................................. 597

* Correspondent Author:
E-mail address: asil.bilgicemel@aglik.gov.tr (A. Bilgic).

https://doi.org/10.1016/j.jiwjd.2021.08.013
2352-6475/© 2021 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
What is known about this subject regarding women and their families?

- Livedoid vasculopathy (LV) affects women more often than men (female: male ratio ~3:2). This increased risk of LV in women might be related to sex-specific physiological conditions, such as pregnancy, or a higher incidence of LV-associated conditions, such as connective tissue diseases, hypercoagulable states, and venous stasis in women. Furthermore, various inherited coagulation abnormalities have been identified in patients with LV; thus, possible underlying genetic abnormalities must be uncovered to protect other family members.

- Disfiguring complications, especially painful ulcers and scarring, could have detrimental effects on social and personal relationships and substantially deteriorate patients’ quality of life.

- The literature published to date is scarce and/or absent regarding specific considerations for women, the differences between sexes in terms of genetic susceptibility, therapeutic choices, and outcomes, as well as quality of life and long-term results.

What is new from this article as messages for women and their families?

- Significantly few high-quality studies have addressed problems regarding livedoid vasculopathy (LV) and therapeutic choices.

- Reviews and consensus papers are of utmost importance because they show the scientific gap regarding the disease and treatment for specific groups. The current review reveals an urgent need to study and identify specific approaches regarding epidemiologic differences between the sexes, underlying conditions, quality of life, management, and long-term results for LV.

- Recently, an association of LV with certain genetic variants, especially PAI-1–675 4G/5G, is highlighted.

- Anticoagulants are the most reported monotherapy recently and can be selected in patients with thrombophilia and/or without significant improvement after antiplatelet treatment. Rivaroxaban is preferred due to its advantage of oral administration and the un necessity of international normalized ratio follow-up, which increases patient compliance.

Introduction

Livedoid vasculopathy (LV) is a rare, chronic, and recurrent thrombo-occlusive disease of the veins supplying the upper parts of the skin (Alavi et al., 2013). It has had several names due to its complicated nature, including livedo vasculos, segmental hyalinizing vasculitis, livedo reticularis with summer ulceration, Milian white atrophy, atrophy blanche en plaque, and painful purpuric ulcers with a reticular pattern of lower extremities (or PURPLE) since its first description by Milian (1929). However, Bard and Winkelmann (1967) first used the term livedoid vasculopathy in 1967. The primary pathology is hypercoagulability, although inflammation plays a secondary role. Thus, LV is different from inflammatory vasculitis and classified as a coagulating disorder, a vasculopathy, which occurs when a thrombus forms in the arterial lu-

men and compromises blood flow. LV shows a chronic course with periodic and recurrent exacerbations, often affecting the legs bilaterally (Criado et al., 2011). Definite diagnosis of LV is based on clinical manifestations and histopathological findings. LV substantially affects patients’ quality of life because of its recurrent clinical course, pain, and scarring.

Early diagnosis and treatment before ulcer development can reduce pain and prevent the development of scarring, disfigurement, and other complications. Therefore, a multidisciplinary team approach involving professionals from pathology, rheumatology, hematology, radiology, cardiac surgery, infectious disease, and oncology is imperative for accurate diagnosis, identification of underlying conditions, and optimal treatment.

The literature published to date is scarce and/or absent regarding specific considerations for women, differences between the sexes in terms of genetic susceptibility, therapeutic choices and outcomes, quality of life, and long-term results. This review provides a detailed overview of epidemiology, pathogenesis, clinical features, and treatment of the disease. However, in this comprehensive review, we have mainly focused on key issues regarding diagnosis/differential diagnosis and clinical management of LV with a holistic approach. In addition, we tried to identify the research gap in the literature to form the basis for further research.

Epidemiology

LV often occurs in young to middle-aged adults and affects women more often (female: male ratio ~2:3; Criado et al., 2011; Gonzalez-Santiago and Davis, 2012; Micieli and Alavi, 2018; Winkelmann et al., 1974). This increased risk for LV in women might be related to sex-specific physiological conditions, such as pregnancy (Sankar and Hinshaw, 2009) or a higher incidence of LV-associated conditions, such as connective tissue diseases, hypercoagulable states, and venous stasis, in women. The incidence of LV is estimated at 1:100,000 (Alavi et al., 2013; Criado et al., 2011).

Fig. 1. Diagnostic approach to livedoid vasculopathy.
Epidemiologic data also suggest that there is a 5-year delay in the adequate diagnosis and management of this condition (Freitas et al., 2018). Possible reasons for the delay in diagnosis can be that patients do not consult dermatologists in the early stages of cutaneous findings, cutaneous lesions usually initially cause minimal subjective complaints, and the current clinical picture can be confused with cutaneous findings that may accompany venous insufficiency, especially venous ulcers.

Pathogenesis

LV pathogenesis is not yet fully known. Initially, it was considered to be vasculitis. However, recent consensus suggests that changes in the local or systemic control mechanism of coagulation lead to the formation of fibrin thrombi in superficial dermal vessels. The thrombotic effect results from defects in the endothelial cell plasminogen activation, platelet dysfunction, or enhanced fibrin formation (Vasudevan et al., 2016). This dermal-vessel thrombosis leads to superficial tissue ischemia and necrosis, causing ulceration and debilitating pain (Amato et al., 2006; Hairston et al., 2006; Vasudevan et al., 2016). Low tissue perfusion further leads to poor wound healing and ineffective killing of microorganisms by leukocytes, enhancing the chance of infection (Vasudevan et al., 2016).

Patients with LV also show decreased flow-mediated vasodilation of the brachial artery, signifying endothelial dysfunction and decreased production or activity of nitrous oxide in endothelial cells, supporting the contribution of endothelial damage to LV (Alavi et al., 2013; Yang et al., 2012). Therapeutic response to immunosuppressive and immunomodulatory agents and association with other autoimmune disorders also supports the involvement of autoimmunity in etiopathogenesis. Increased perfusion pressure at the ankles also appears to play an important role (Vasudevan et al., 2016). LV can be categorized as primary (idiopathic) or secondary LV, in which a known underlying condition causes the disease (Alavi et al., 2013).

Although some mechanisms in the etiopathogenesis of LV and COVID-19–associated livedoid lesions have similar features, COVID-19 infection-causing LV has not yet been reported (Llamas-Velasco et al., 2020). Recently, COVID-19-induced recurrence of LV in a 34-year-old female patient with no other comorbidities or coagulative disorders has been reported (Valentim et al., 2021).

Histopathology

A clinical presentation of LV is characteristic; however, biopsy is necessary to exclude other entities in the differential diagnosis and confirm LV diagnosis. Characteristic histological findings include thickening (endothelial proliferation) or hyalinized degeneration of the subintimal layer of superficial dermal vessels along with intraluminal fibrin deposits, intraluminal thrombosis, red blood cell extravasation, and scarce perivascular lymphocytic infiltration (Bard...
Fig. 5. Algorithmic therapeutic approach of livedoid vasculopathy.
and Winkelmann, 1967; Haunson et al., 2012). No signs of true vasculitis in the form of leukocyte infiltrate on the vessel walls are seen (Criado et al., 2011; Hesse and Kutzner, 2008). Thus, the histopathological findings allow clinicians to better classify LV as vasculopathy instead of immune-complex-mediated necrotizing vasculitis (Fig. 1; Criado et al., 2011; McCalmont et al., 1992).

Histopathological findings depend on the age of the lesion, and due to the focal and segmental involvement pattern of LV, classic histopathological findings may not be observed by the biopsy. Thus, attention should be given to the appropriate biopsy method (Alavi et al., 2013). Early lesions show intraluminal hyaline thrombi in small vessels in the mid- and papillary dermis and fibrinoid materials in the vessel walls and perivascular stroma (Alavi et al., 2013; Georgesen et al., 2020). Fully developed lesions show thickening and hyalinization of vessel walls with endothelial edema and proliferation, along with intraluminal fibrin thrombi, dermal sclerosis, and scarring. Multiple biopsies could be necessary for definitive diagnosis; however, some experts suggest that multiple biopsies could complicate the healing of the ulceration (Fig. 1; Alavi et al., 2013; Criado et al., 2011; Haunson et al., 2012).

Apart from routine histopathology, direct immunofluorescence (DIF) is used. DIF demonstrates immunoglobulin deposition (multiple immunoreactants, especially C3 and immunoglobulin IgM, followed by IgA, and IgG), fibrin, and complement components, although DIF findings are thought to be nonspecific and nondiagnostic (Criado et al., 2011; Khenifer et al., 2009; Nuttawong et al., 2021). In the literature, the incidence of positive DIF in patients with LV ranged from 42.9% to 100% (Criado et al., 2014; Hsiao and Wu, 2010; Nuttawong et al., 2021; Schroeter et al., 1971; 1975). Older patients and more recent lesions (<6 months) had a significantly higher percentage of positive DIF results for LV (Nuttawong et al., 2021).

### Clinical features

Patients with LV often have a history of painful recalcitrant ulcers and whitish scars near the ankles. Burning pain is a pathognomonic prodromal symptom of this entity. Physical examination might reveal lesions in different stages of evolution. The typical clinical appearance of LV consists of three main findings: livedo racemosa, skin ulcerations, and atrophic blanche (Fig. 1; Alavi et al., 2013).

Livedo racemosa is distinguished by vivid, erythematous to purpure, network-like lines, mainly due to abnormal perfusion of cutaneous microcirculation (Fig. 2). Naturally, LV is not the only disease in which livedo racemosa can be seen; however, it is generally regarded clinically as an early manifestation of LV. Livedo reticularis and livedo racemosa (broken net pattern) are precursor lesions before ulceration. Purpuric macules, papules, or retiform or stellate purpura (especially considered as a hallmark lesion) are other important initial findings (Fig. 3). They are often distributed on the ankles, dorsum of the feet, and the lower extremities and usually occur symmetrically. However, some studies also showed lesions on the upper extremities in a small proportion of patients (Lee and Cho, 2020; Rujitharanawong et al., 2021). This is followed by acute-onset, painful, and small crusted ulcers. Ulcers characterize the active stage of the disease. Excruciating pain, causing difficulties in daily life, is a clue for early diagnosis because it precedes ulceration (Vasudevan et al., 2016). Ulcers, characterized by a punched-out appearance on the perimalleolar area, heal within 3 to 4 months with atrophic blanche, small residual round or stellate porcelain-

Table 1: Differential diagnosis and their specific characteristic findings

| Differential diagnosis                        | Distinguishing features                                                                 |
|-----------------------------------------------|----------------------------------------------------------------------------------------|
| Chronic venous insufficiency                  | Varicose veins, superficial telangiectasias, edema of the lower limbs, stasis dermatitis, abnormal venous Doppler ultrasound findings |
| Peripheral arterial disease                   | Pale skin, claudication, painful ulcerations, abnormal arterial Doppler ultrasound findings, abnormal ankle-brachial index test |
| Cutaneous polyarteritis nodosa                | Subcutaneous tender nodules on the legs, ulcerations, digital gangrene, medium vessel involvement, mononeuritis multiplex |
| IgA vasculitis                                | Age <10 y, organ involvement (joint, gastrointestinal and renal), IF; IgA               |
| Cutaneous leukocytoclastic angiitis            | Clinical and hematoxylin and eosin findings, such as IgA vasculitis; no organ involvement |
| IgM/IgG vasculitis                            | Urticaria ± necrotic/ulcerous lesions, IF; IgM/IgG                                      |
| Cryoglobulinemic vasculitis                   | Cold exacerbation, Raynaud’s phenomenon, acrocyanosis, renal involvement, IF; cryoglobulin II/III |
| Recurrent macular vasculitis                  | Recurrent and short-term hemorrhagic macules, hypergammaglobulinemia positive           |
| Normocomplementemic UV                        | Urticaria >24 h, postinflammatory pigmentation, ± hypercomplementemia                   |
| Hypocomplementemic UV                         |                                                                                         |
| Eosinophilic granulomatosis with polyangiitis | ANCA+, eosinophil-rich histopathology, respiratory (rhinitis, asthma history), renal (hematuria), neurological (neuropathy, mononeuritis multiplex), cardiac (eosinophilic cardiomyopathy) and gastrointestinal (polyposis, nausea, vomiting, abdominal pain) involvement |
| Granulomatosis with polyangiitis              | p-ANCA or c-ANCA positive, retiform purpura-like lesions and reticulated ulcerations, pulmonary and renal disease (glomerulonephritis) |
| Microscopic polyangiitis                      | p-ANCA positivity, retiform purpura-like lesions and reticulated ulcerations, dermal granuloma, mononeuritis multiplex, pulmonary and renal disease |
| Sneddon syndrome                              | Livedo racemosa with cerebrovascular stroke                                             |
| Others in differential diagnosis of atrophic  | Sickle cell disease, hydroxyurea ulcers, malignant atrophic papulosis, polycythemia vera, thalassemia, essential thrombocytosis, chronic myeloid leukemia |
| blanche                                       |                                                                                         |

ANCA, antineutrophil cytoplasmic antibody; IF, immunofluorescent; Ig, immunoglobulin; UV, urticarial vasculitis

### Genetics

Several hereditary and acquired coagulation abnormalities are involved in LV, including polymorphisms in methylenetetrahydrofolate reductase (MTHFR), plasminogen activator inhibitor-1 (PAI-1), prothrombin, and factor V. The associations between LV and genetic abnormalities show geographical or ethnic differences. A recent systematic review investigating genetic variations identified that PAI-1-675 4G/5G was the most common, accounting for 85.26% of cases (n=81 of 95), followed by PAI-1 A844G, MTHFR C677T, and MTHFR A1298C variants. Prothrombin G20210A and factor V G1691A were mainly present in patients with LV from Europe, North America, and South America (Gao and Jin, 2021).
white atrophic scars surrounded by hyperpigmentation and telangiectasias (Fig. 4; Alavi et al., 2013; Criado et al., 2011; Weishaupt et al., 2019).

Although systemic involvement is not a feature of idiopathic LV, peripheral nervous system involvement (paresthesia or hyperesthesia, mononeuritis multiplex) can be seen due to multifocal thrombosis and ischemia of the vasa nervorum and is the only known extracutaneous manifestation of LV (Criado et al., 2011; Tubone et al., 2013; Vasudevan et al., 2016). A French observational study has revealed a high incidence of peripheral neuropathy (50% of patients), which has been described rarely in the existing literature (Gan et al., 2012; Gardette et al., 2018). Due to the limitations of conventional diagnostic techniques (electromyography, nerve biopsy), which mainly work with large nerve fibers, a diagnosis of peripheral neuropathy requires special investigations. Gardette et al. (2018) suggested that most patients with LV have neuropathic pain that persists after healing of ulcers despite a normal electromyography; peripheral neuropathy is probably underestimated. Nerve biopsies also reveals an ischemic process, showing that LV is not only a cutaneous but also a peripheral neurological disease (Gardette et al., 2018). Other systemic and multiorgan involvement might be present in secondary LV associated with autoimmune connective tissue disorders. A dermoscopic examination of LV could show central shallow crustated ulcers, ivory–white atrophic scar-like areas, pigment network or ivory–white structureless areas with a peripheral pigment network, and telangiectatic irregular, linear, and glomerular vessels (Hu et al., 2017; Shen et al., 2019; Wen et al., 2020).

**Diagnosis and differential diagnosis**

The diagnostic criteria of LV are not well defined, and no treatment guidelines are available (except Delphi-consented expert recommendations; Alavi et al., 2013). A detailed history, dermatological examination, and laboratory work-up are essential for excluding other diseases in the differential diagnosis, demonstrating associated conditions, and, therefore, a diagnosis of LV.

When LV is clinically suspected, a skin biopsy should be taken to confirm the diagnosis. A fusiform incisional biopsy containing subcutaneous fat is the most appropriate biopsy. Alternatively, a 4 to 6 mm punch biopsy may be performed. The best place for a biopsy is the edge of a new ulcer; the biopsy specimen should contain 2 to 3 mm of marginal skin and the eventual ulcer (Alavi et al., 2013).

A differential diagnosis of other common causes of atrophic blanche should be the first step in the clinical work-up. The most common diseases to be considered in the differential diagnosis are lower extremity chronic venous insufficiency, peripheral arterial vascular disease, and vasculitis. Along with clinical signs, abnormal arterial Doppler ultrasound findings and ankle-brachial index test support the diagnosis of peripheral artery diseases. Another main differential diagnosis is cutaneous polyarteritis nodosa, which produces similar cutaneous lesions on the legs. A proper skin biopsy can distinguish LV from vasculitis.

Despite all efforts, no associated factor can be detected in approximately 20% of all cases (idiopathic LV). In the remaining patients, connective tissue disorders, malignancy, hypercoagulable states, and thrombophilia are the most important associated factors (Table 1; Fig. 1; Alavi et al., 2013; Weishaupt et al., 2019).

**Laboratory testing**

When the diagnosis is confirmed histopathologically, further review of possible underlying diseases should be undertaken. Assessment, of course, should begin with a complete history, review of systems, and physical examination to assess findings suggestive of underlying diseases. Laboratory tests for thrombophilia are recommended in all patients (Ishibashi et al., 2009; Sankar and Hinshaw, 2009; Winkelmann et al., 1974). Further examination, such as coagulating factors and their mutations, are required for hereditary or acquired thrombophilia.

Detailed laboratory research for connective tissue disorders, such as systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, scleroderma, and mixed connective tissue disease, should be performed in the presence of relevant findings suggestive of these diseases. In addition, Ig kappa and lambda chain levels, protein electrophoresis, and immunofixation should be performed when paraproteinemia or solid organ cancers are suspected. Again, in the presence of an underlying in-

**Table 2**

**Laboratory testing for livedoid vasculopathy**

| Hypercoagulable states/ fibrinolytic disorders/ thrombophilia | Factor V Leiden and prothrombin G20210A mutation, protein C, protein S, anti-thrombin-III deficiency, PT/PTK, aPTT, fibrinogen, D-dimer, lupus anticoagulant, lipoprotein (a), serum homocysteine, MTHFR-C677T polymorphism, prothrombin-C20210A mutation, serum fibrinopeptide A, levels of serum complements (C3, C4), fibrinogen, plasminogen-activator inhibitor activity, antiphospholipid antibodies, cryoglobulin, cold agglutinins and cryofibrinogen, Ig light chain (kappa and lambda) levels, serum folic acid, vitamin B12 and vitamin B6 levels |
|---|---|
| Connective tissue diseases (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, scleroderma, primary Sjögren’s syndrome, polyarteritis nodosa, and undifferentiated connective tissue diseases) | Levels of serum complements (C3, C4), ANCA, ANA, anti-Ro, anti-La, anti-CCP, rheumatoid factor, cryoglobulin, cryofibrinogen, plasminogen activator inhibitor, anti-beta-2 glycoprotein I, antiphospholipid antibodies (lupus anticoagulant), antcardiolipin antibodies (IgM and/or IgG), and IgM antiphosphatidylserine |
| Malignancy (Hematological (myeloproliferative disorders, paraproteinemias, multiple myeloma) and solid organ malignancies) | Ig light chain (kappa and lambda) levels, protein electrophoresis, immunofixation, lipoprotein (a) levels |
| Infections | Anti-streptolysin-O, throat culture, hepatitis B, hepatitis C, enzyme-linked immunosorbent assay for HIV, COVID-19, swab wound culture, and tissue cultures |
| Conditions associated with stasis (chronic venous hypertension of the limbs, varicose veins) | Venous Doppler ultrasound, arterial Doppler ultrasound, ankle-brachial/toe-brachial pressure index, venous duplex imaging, plethysmography, and transcutaneous oximetry cardiovascular surgery consultation |
| Assessing tissue ischemia | Transcutaneous oxygen pressure or partial pressure of oxygen by transcutaneous oximetry adjacent to the ulcer, Doppler flowmetry, laser Doppler perfusion imaging, and microlymography |
| Pregnancy | Urine human chorionic gonadotropin |
| Other | Complete blood count, comprehensive metabolic panel, urinalysis, erythrocyte sedimentation rate, C-reactive protein, peripheral smear, fecal occult blood |

ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; aPTT, activated partial thromboplastin time; CCP, cyclic citrullinated peptide antibodies; ENA, extractable nuclear antigen antibody; Ig, immunoglobulin; MTHFR, methylenetetrahydrofolate reductase; PT, prothrombin time; PTT, partial thromboplastin time with kaolin
| Treatment (reference) | Mechanism of action | Dose | Side effects |
|------------------------|----------------------|------|--------------|
| Aspirin (acetylsalicylic acid) (Acland et al., 1999; Castillo-Martínez et al., 2014; Criado et al., 2013; Drucker and Duncan, 1982; Gan et al., 2012; El Khoury et al., 2012; Krueger et al., 2020; Lee et al., 2003; Okada et al., 2008) | Cyclooxygenase inhibitor; suppresses thromboxane A2 and prostaglandin I2; promotes vasodilation; prevents platelet aggregation and thrombus formation; improves ulcer healing | 75–325 mg, higher doses (up to 325 mg, 3 × 1 daily) offering better results | Angioedema, urticaria, gastrointestinal bleeding, Reye's syndrome, salicylism (central nervous system, tinnitus) |
| Pentoxifylline (Criado et al., 2021; Feng et al., 2014; Gan et al., 2012; Krueger et al., 2020; Lee et al., 2003; Marzano et al., 2003; Meiss et al., 2006; Sams, 1988; Song et al., 2020; Yong et al., 2012) | Competitive nonselective phosphodiesterase inhibitor; reduces inflammation; decreases blood viscosity; modifies red blood cell structure to reduce exocytosis; increases the inflow circulation; reduces platelet aggregation and thrombus formation | 400 mg every 3 × 1 daily | Dyspepsia, nausea, vomiting, abnormal liver function, alopecia |
| Dipyridamole (Agirbasli et al., 2011; Drucker and Duncan, 1982; Krueger et al., 2020) | Phosphodiesterase inhibitor; inhibits the synthesis of thromboxane A2; stimulates release of prostaglandin I2; inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP (inhibitor of platelet function and aggregation) | Initial: Dose of 50 mg, twice daily (up to 75 mg 4 × 1) | Bleeding, dizziness |
| Clopidogrel (Kunzler and Chong, 2018) | Antiplatelet agent; inhibits prostaglandin synthesis; irreversibly binds to P2Y12 ADP receptors on platelets and prevents platelet aggregation | 75 mg once daily | Hemorrhage, vomiting, pancytopenia, thrombotic thrombocytopenic purpura, hypersensitivity reactions |
| Ticlopidine (Hegemann et al., 2002; Okada et al., 2008) | Prodrug that is metabolized to an active form; blocks ADP receptor that is involved in GP IIb/IIIa receptor activation leading to platelet aggregation | 250 mg twice daily | Aplastic anemia, thrombotic thrombocytopenic purpura, black-box warning of neutropenia, bleeding, hepatic impairment |
| Buffomedil hydrochloride (Criado et al., 2011) | Antiplatelet effect; nonspecific calcium channel antagonist and alpha-blocker; increases inflow circulation | Oral 150 mg, 3–4 × daily or 300 mg twice daily | Flushing, headache, vertigo, dizziness, gastrointestinal discomfort |
| Bepridil sodium (Tsutsui et al., 1996) | Analog of PGII2; stable, orally active prostacyclin analog with vasodilatory, antiplatelet and cytoprotective effects | 120 μg/day initially and at a dose of 60 μg/d subsequently 0.25 mg/kg IV bolus followed by continuous IV infusion of 0.125 μg/kg/min for 12 hr | Headache, flushing, diarrhea, leg pain, and nausea |
| Abciximab (Vasudevan et al., 2016) | Monoclonal antiplatelet agent that inhibits binding of fibrinogen, von Willebrand factor, and other adhesive molecules | | |
| Sargoprelate hydrochloride (Osada et al., 2010; Vasudevan et al., 2016) | Antagonist of 5-hydroxytryptamine 2A receptor (serotonin); antiplatelet and vasodilator effects | Orally 300 mg/day | Hemorrhage, thrombocytopenia, agranulocytosis, jaundice |
| Anticoagulant | Vitamin K antagonist; inhibits vitamin-K dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors; increases fibrinolytic activity | Oral/IV; 2–5 mg once daily for 1–2 days, then adjust dose based on international normalized ratio (maintained between 2 and 3) Maintenance: 2–10 mg oral/IV once daily | Teratogen, bleeding, jaundice, necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions |
| Warfarin (Browning and Callen, 2006; Di Giacomo et al., 2010; Kavala et al., 2008; Nakamura et al., 2011; Nakayama et al., 2017; Noda et al., 2011; Osada et al., 2010; Saoji and Madke, 2017; Vieira et al., 2016; Yoshiba et al., 2018) | Decreases blood viscosity; increases fibrinolytic activity; increases activity of tissue plasminogen activator | Dose of 5000 U/12 hr, subcutaneously | Bleeding, thrombocytopenia |
| LMWH (enoxaparin, dalteparin, nadroparin) (Abou Rahal et al., 2012; Di Giacomo et al., 2010; Francis and Barrete. 2004) | Decreases blood viscosity; increases fibrinolytic activity | Enoxaparin 40 mg/day or 100 IU/g per injection bidaily, dalteparin sodium 5000 IU/day, subcutaneously | Late hypersensitivity, injection site reactions, increase in liver enzymes |
| Rivaroxaban (Chen et al., 2017; Drabik et al., 2014; Drepup and Goerce, 2017; Evans et al., 2015; Franco Marques and Criado, 2018; Jiménez-Gallo et al., 2018; Kerk et al., 2013; Lee and Cho, 2020; Lee and Kim, 2016; Leisenring et al., 2020; Miguel et al., 2020; Weishaupt et al., 2016, 2019; Winchester et al., 2015) | Direct inhibitor of factor Xa; new LMWH; decreases blood viscosity; increases fibrinolytic activity | 10 mg bidaily, orally | Hypermenorrhoea, nose bleeding, bleeding tendency during dental procedures, and hemorrhaxis |
| Other vitamin K antagonists (preprohormone, acenocoumarin, fluindione) (Francés and Barrete. 2004) | Decreases blood viscosity; increases fibrinolytic activity | Require monitoring international normalized ratio (maintained between 2–3) Oral 250 lipasemic units 3 × 1 daily | Bleeding tendency |
| Sulodexide (Song et al., 2020) | Highly purified mixture of glycosaminoglycans, including dermatan sulfate and LMWH | 10 mg IV every 4 hr/day, 14 day | Transient gastrointestinal intolerance, nausea, dyspepsia |
| Fibrinolytics | Fibrinolysis of microvascular thrombi; restores the circulation; promotes wound healing | | Bleeding, allergic reactions |
| Treatment (reference) | Mechanism of action | Dose | Side effects |
|-----------------------|---------------------|------|--------------|
| **Antiplatelets**     |                     |      |              |
| Danazol/stanozolol    | Synthetic steroids and pituitary gonadotropin inhibitors; have fibrinolytic activity | Danazol: 200 mg/day or 4 mg/kg/day for a short duration of 4–12 weeks Stanozolol: 4 mg/day | Hirutism, acne, steroid-like side effects, alopecia, menstrual disturbances, clitoral hypertrophy |
| Vasodilators          |                     |      |              |
| Nifedipine            | Dihydropyridine calcium channel blocker; reduces vasoconstriction; decreases peripheral arterial vascular resistance; increases supply of oxygen | 10–20 mg 3 × 1 per day | Hypotension, sinus node dysfunction, atrioventricular node dysfunction, reflex tachycardia, Headache, diarrhea, tachycardia, hypotension, cardiac arrhythmias |
| Cilostazol            | Quinolinone derivative; phosphodiesterase III inhibitor; antiplatelet agent and vasodilator | 100 mg twice daily | Severe prolonged hypotension |
| **Anti-inflammatory** |                     |      |              |
| Colchicine            | Alkaloid; inhibition of inflammation caused by tubulin disruption; anti-inflammatory effects with neutrophil inhibition | Oral 0.5 mg, 2 × 3 × daily | Gastrointestinal disturbance, including abdominal pain, nausea, vomiting, diarrhea, Nasal congestion, syncope, anemia, hallucinations |
| Dapsone               | Sulfone drug; anti-inflammatory effects with neutrophil inhibition; immunosuppressive and antibacterial properties | Oral doses of 50–100 mg/day | Headache, facial edema, paresthesia of the lips, nausea, rash, itching, metallic taste |
| Sulfasalazine         | Sulphapyridine metabolite; anti-inflammatory and/or immunomodulatory properties; inhibition of platelet aggregation by 5-aminosalicylic acid prevents cytokine release from mononuclear cells | 500 mg, 3 × 1 daily, orally | Headache, facial edema, paresthesia of the lips, nausea, rash, itching, metallic taste |
| **Immunosuppressants** |                     |      |              |
| Prednisolone          | Anti-inflammatory action; antifibrinolytic effect; immunosuppressive effect | 0.5–1 mg/kg/day (prednisolone or equivalent) | Steroid side effects |
| Azathioprine          | Prodrug of 6-mercaptopurine; inhibits purine synthesis along with inhibition of B and T cells | 2–3 mg/kg/day | Bone marrow hypoplasia, hepatotoxicity, infection |
| Cyclophosphamide      | Alkylating agent; cytotoxic effect due to cross-linking of strands of DNA and RNA; inhibition of protein synthesis; immunosuppressive effect | 1.5–2.5 mg/kg/day | Neutropenia, alopecia, nausea, vomiting, diarrhea, sterility, birth defects, mutations, cancer |
| Cyclosporine          | Calcineurin inhibitor; potent immunomodulatory agent; suppresses lymphocyte activity; inhibits expression of tissue factor of monocytes, which is a vital component in triggering the coagulation cascade | 3–5 mg/kg/day | Hypertrichosis, gingival hyperplasia, nephrotoxicity, hypertension |
| Supplements           | Required for homocysteine remethylation; necessary to maintain adequate plasma homocysteine and serum folate levels | Vitamin B6 (1500 μg/day) and vitamin B12 | Abdominal cramps, diarrhea, sleep disorders, irritability, confusion, stomach upset, Nausea, stomach upset, diarrhea, drowsiness, flushing, numbness, tingling |
| Vitamin B12/B6         | Additional supplementation along with folic acid | 5 mg/day | (continued on next page) |
fection suspicion, tests for hepatitis and HIV infection should be performed (Table 2).

**Treatment**

Treatment of LV is very challenging for physicians. Because the incidence of LV is relatively low, there are no large series of studies on its treatment. Therefore, the level of evidence is not high, and treatment recommendations are generally based on case series, small clinical trials, or expert recommendations. No single therapeutic approach is effective for all patients. Furthermore, there are no predictive clinical or biologic indicators for the severity or frequency of LV flares. For this reason, many options are often used in combination. Moreover, there is no fixed endpoint for treatment in patients who respond to treatment. Once the ulcer has healed, treatment may be discontinued; however, long-term treatment may be necessary to maintain healing. Treatment selection can be based on cost, adherence, patient comorbidities, and clinical experience. The main treatment options are presented in Table 3. Our approach is reviewed herein, and the therapeutic algorithmic approach is presented in Figure 5.

Although the best approach to treatment is unclear, general measures (e.g., wound care, smoking cessation, compression, and pain management) are important components of LV therapy along with pharmacological treatment. Wound care should include maintaining a moist wound environment and controlling superinfection. Patients should be encouraged to stop smoking because of the negative effects of smoking on wound healing. Compression therapy is also helpful in patients with venous insufficiency. Improvement may be due to the stimulating effect of compression on fibrinolytic activity and controlling edema. Pain secondary to livedoid vasculopathy can be severe. Nonsteroidal anti-inflammatory drugs, such as indomethacin or acetaminophen, can be used. Tricyclic antidepressants, gabapentin, pregabalin, or carbamazepine may be preferred for neuropathic pain and are valuable for patients with persistent painful ulcerations (Alavi et al., 2013; Micieli and Alavi, 2018).

The first-line therapeutic step is antiplatelet therapy (aspirin, dipyridamole, and pentoxifylline). Aspirin (300 mg once daily) is preferred, especially as the initial therapy for patients without an identified thrombophilia and/or with sickle cell trait. Tolerability, wide availability, and low cost are important advantages of this compound. Dipyridamole and pentoxifylline (600 mg twice daily) can be favored in combination with aspirin in unresponsive cases or alone in patients who cannot tolerate aspirin. In patients with identified thrombophilia and/or without significant improvement after antiplatelet treatment, anticoagulants can be used. Low molecular weight heparin (1 mg/kg/d) or rivaroxaban (2×15 mg in the first week, then continue with 20 mg once daily) are typically used at our center. Anticoagulants were the most reported monotherapy in a recent systematic review by Micieli and Alavi (2018). Rivaroxaban is often the treatment of choice in recent years due to the advantage of oral administration and the unnecessary of international normalized ratio follow-up, which increases patient compliance.

Anabolic steroids (prednisolone and equivalents, danazol 4 mg/kg/d) were the second most used and effective treatment in clinical trials. They inhibit coagulation while increasing fibrinolysis. They can be the next step, especially in patients with connective tissue diseases, hyperfibrinogenemia, and other occlusive conditions. Systemic steroids can also be added to the main treatment to achieve rapid disease control at any timepoint.

In resistant cases, preference for therapeutic choices is based on availability, clinical experience, and patient-related factors (comorbidities, age, sex, compliance). Intravenous Ig, hyperbaric oxygen treatment (1.5–2-hour sessions, three times daily for 3–4 weeks) and fibrinolytics (recombinant tissue plasminogen activator, 10 mg/d for 14 days) have also been reported to be effective alternatives. These treatments would be more suitable for refractory LV due to high cost and difficulties in patient compliance. All other therapeutic options are summarized in Table 3. Hydroxychloroquine in patients with systemic lupus erythematosus and antiphospholipid antibody syndrome, and colchicine in patients with vasculitis can be reasonable options in combination with antiplatelet and/or anticoagulant therapies. Vasodilators (used as maximum tolerated dose), anti-inflammatory agents, immunosuppressives, and psoralen-ultraviolet A could be used as third-line options. Vitamin supplements, especially folic acid and vitamin B12/B6, are required for homocysteine remethylation; thus, they can be added to treatment. All these agents are used often in combination with antiplatelets and anticoagulants (Alavi et al., 2013; Micieli and Alavi, 2018).

**Table 3 (continued)**

| Treatment (reference) Antiplatelets | Mechanism of action | Dose | Side effects |
|------------------------------------|---------------------|------|--------------|
| Intravenous immunoglobulin (Amital et al., 2000; Bounfour et al., 2013; Kim et al., 2015; Koller et al., 2021; Kreuter et al., 2004; Monshi et al., 2014; Oravec et al., 1995; Ozden et al., 2020; Pitarch et al., 2005; Ravat et al., 2002; Tuchinda et al., 2011) | Acts by inhibiting Fc receptor function in macrophages, T cells, and B cells, leading to decreased cytokine production; reduces immune complex deposition in small vessels; inhibits thromboxane synthetase; decreases vasoconstriction | Monthly infusions in the dose of 0.4–2 g/kg over 2–3 consecutive days | Allergic reactions, headache, flushing, chills, myalgia, wheezing, tachycardia, hypotension |
| Hyperbaric oxygen (Banham, 2013; Bhutani et al., 2012; Bollmann et al., 2011; Fernandes, 2009; Juan et al., 2006; Ray et al., 2015; Verma, 2013; Yang et al., 2003) | Enhances tissue oxygenation and microvascular perfusion by stimulating nitric oxide synthesis; accelerates angiogenesis and fibrolysis; accelerates fibroblast proliferation; diminishes tissue reperfusion injury; increases growth of granulation tissue; bacteriostatic and bactericidal effects | Pure oxygen or 100% 1.5–2 hr, 1–3 × daily | Lung damage, changes in vision, oxygen poisoning |
| Pсорalen plus ultraviolet A (Choi and Hann, 1999; Lee et al., 2001; Tuchinda et al., 2005) | Decreases ability of lymphocytes to respond to cytokine production; induces release of immunosuppressive factors | 2–3 × per week | Sunburn-like reaction, phototoxic erythema, skin ageing and skin cancer |
| Rituximab (Zeni et al., 2008) | Monoclonal anti-CD20 antibody | 1.0 g, two infusions, 14 days apart | Neonatal harm, infection risk, severe immunosuppression |
| Antitumor necrosis factor (etanercept) (Gao and Jin, 2020) | Anti-inflammatory properties; act mainly by close interaction between various inflammatory cytokines and coagulation | 25–50 mg once a week for 12 consecutive weeks | Infection risk, immunosuppression |

ADP, adenosine diphosphate; cAMP, IV, intravenous; LMWH, low molecular weight heparin; PGJ2, prostaglandin I2
LV is associated with a variety of underlying conditions, and no single etiology has been identified. Since the therapeutic approach should be modified according to etiopathogenetic mechanisms, possible systemic associations should be investigated. Several therapeutic options with different success rates are being used. However, randomized controlled trials with a high evidence level should be performed to determine the best therapeutic approach in the treatment of LV. Furthermore, a multidisciplinary approach is necessary for effective and proper treatment.

Conflicts of interest
None.

Funding
None.

Study approval
N/A

References
Abou Rahal J, Ishak RS, Otrock ZK, Kibbi AG, Taher AT. Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: Treatment with low-dose molecular-weight heparin. J Thromb Thrombolysis. 2012;34(4):541–4.
Acldam KM, Darvay A, Wakelein SH, Russell-Jones R. Livedoid vasculitis: A manifestation of the antiphospholipid syndrome? Br J Dermatol. 1999;140(1):131–5.
Agibasili M, Eren M, Eren F, Murphy SB, Serdar ZA, Seckin D, et al. Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. J Thromb Thrombolysis. 2011;32(1):59–63.
Alavi A, Hafner J, Dutz JP, Mayer D, Sibbald RG, Criado PR, et al. Livedoid vasculathy: An in-depth analysis using a modified Delphi approach. J Am Acad Dermatol. 2013;69(6):1033–42 e1.
Amato L, Chiarii C, Bertì S, Massi D, Fabbi P. Idiopathic atrophic blush. Skinned. 2006;5:151–4.
Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol. 2000;18:404–6.
Anderson CA, Berosford SA, Mc cerran D, Lampe JW, Deeb S, Feng Z, et al. Response of serum and red blood cell folate concentrations to folic acid supplementation depends on methyltetrahydrofolate reductase C677T genotype: Results from a crossover trial. Mol Nutr Food Res. 2013;57:637–44.
Antunes J, Filipe P, André M, Fraça A, Milleney C, Marques Gomes M. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: Response to tPA therapy. Acta Derm Venereol. 2010;90(1):91–2.
Barham ND. Livedoid vasculopathy successfully treated with hyperbaric oxygen. Dying Hyperb Med 2013;43(1):35–6.
Bard JW, Winkelmann RK. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967;96:489–99.
Bhutani S, Verma R, Verghese C. Livedoid vasculopathy managed with hyperbaric oxygen therapy. Med J Armed Forces India 2012;68(4):389–91.
Bisalputra P, Kullavanijaya P. Sulphasalazine in atrophic blanche. J Am Acad Dermatol 1993;28(2):275–6 Pr 1.
Bollmann PW, Shumada AK, Michalansy NS, Manhan AR, Giglio AD. Livedoid vasculopathy: fast involution after anticoagulant and hyperbaric oxygen therapy. Einstein (Sao Paulo) 2011;9(2):212–15.
Bounfour T, Bouazzi JD, Bézier M, Petit A, Viguier M, Rybojad M, Bagot M. Intravenous immunoglobulins in difficult-to-treat ulcerated livedoid vasculopathy: Five cases and a literature review. Int J Dermatol. 2013;52(9):1135–9.
Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006;142(1):75–8.
Cardoso R, Gonçalo M, Tellechea O, Maia R, Borges C, Silva JA, et al. Livedoid vasculopathy and hypercoagulability in a patient with primary Sjögren’s syndrome. Int J Dermatol 2007;46(4):431–4.
Castillo-Martínez C, Moncada B, Valdés-Rodríguez R, González FJ. Livedoid vasculopathy (LV) associated with sticky platelets syndrome type 1 (SPS type 1) and enhanced activity of plasminogen activator inhibitor (PAI-1) anomalies. Int J Dermatol 2014;53(12):1495–7.
Chen W, Fan L, Wang Y, Deng X. Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy. J Pain Res 2017;10:621–4.
Choi HJ, Hann SK. Livedo reticularis and livedoid vasculitis responding to PUVA therapy. J Am Acad Dermatol 1999;40(2):204–7 Pt 1.
Khenifer Mofarrah, Magy Irani-Hakime

598

Miguel Kim

lopathy

skin

activity

rier:

vents

evaluating

Livedoid vasculopathy for with antiphospholipid syndrome (APS). Arch Dermatol 1995;131(2):231–2.

Nakamura S, Kishibe M, Nishii K, Hashimoto Y, Takeda K, Mizumoto T, et al. Livedoid vasculopathy: favorable clinical response with low dose warfarin. Eur J Dermatol 2011;21(6):1011–12.

Nakayama T, Mizutani K, Hanamura I, Kato H, Takami A, Takeshita K, et al. Livedoid vasculopathy and popliteal artery occlusion in a patient with SLE deficiency. J Dermatol 2017;44(2):198–201.

Noda S, Asano Y, Yamazaki M, Ichimura Y, Tanaki Z, Takehashi T, et al. Severe livedoid vasculopathy associated with antiphospholipid syndrome. Arch Dermatol 2011;147(5):621–3.

Nutawong S, Chularojanamongkol T, Trakanwittrayak S, Pinkaew S, Chanchamri N, Rujirathanawong C. Direct immunofluorescence findings in livedoid vasculopathy: A 10-year study and literature review. Clin Exp Dermatol 2021;46(3):525–31.

Okada E, Nagai Y, Ishikawa O. A case of widespread livedoid vasculopathy with pain but no systemic symptoms. Acta Derm Venereol 2008;88(3):298–9.

Ogave C, Sonda R, Carayon A, Miller J, Kazatchkine MD, Horvath A. Normal human polyclonal immunoglobulin G (intravenous immunoglobulin) modulates endothelial cell function in vitro. Nephrol Dial Transplant 1995;10:796–800.

Osada Si, Kimura Y, Kawasa S. Case of livedoid vasculopathy with peripheral erythromelalgia successfully treated with low-dose warfarin. J Dermatol 2010;37(1):98–101.

Ozden MG, Ozdemir H, Senturk N. Intravenous immunoglobulin in resistant livedoid vasculopathy: Analysis of a case series. Dermatol Ther 2020;33(2):e13329.

Perez-Delgadillo Rodriguez-Serna I, Carbajal J, Verdie A, Fortea JM. Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulin. Acta Derm Venereol 2005;85(4):374–5.

Porcelli SM, Hayes TJ. Nipidipine treatment of idiopathic atrophic blanche. J Am Acad Dermatol 1986;14(5):381–5.

Ravat FE, Evans AV, Russell-Jones R. Response of livedoid vasculitis to intravenous immunoglobulin. Br J Dermatol 2002;147:166–9.

Ray R, Sharma A, Vasdevan B, Sridhar J, Deo R, Mohanty CS. Livedoid vasculopathy with hyperhomocysteinemia responding to hyperbaric oxygen therapy. Indian J Dermatol 2015;60(5):609–13.

Rizzo SC, Grignani G, Gamba G, Nalli G. Fibrinolysis induced by danazol. Blut 1986;53:351–2.

Rujirathanawong C, Chularojanamongkol T, Trakanwittrayak S, Pinkaew S, Nuttawong S. Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature. Dermatol Ther 2021;34(1):e14569.

Rustin MH, Bunker CB, Dowd PM. Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin. Br J Dermatol 1989;120:101–5.

Samaras JR, Van W. Livedo reticularis. Therapy with pentoxifylline. Arch Dermatol 1988;124(5):684–7.

Sankaran A, Himshaw K. Livedoid vasculopathy and pregnancy. Int J Gynaecol Obstet 2009;107(3):248–9.

Saegye V, Maddie B. Use of low-dose oral warfarin in three cases of livedoid vasculopathy. Indian J Dermatol 1977;2(2):508–11.

Schoefer AL, Copeman JW, Jordan RE, Sams JR WM, Winkelman RK. Immunofluorescence of cutaneous vasculitis associated with systemic disease. Arch Dermatol 1971;104:254–9.

Schoenbucher M, Diaz-Perez JL, Winkelman RK, Jordan RE. Livedo vasculitis (the vasculitis of atrophic blanche). Immunohistopathological study. Arch Dermatol 1975;111:188–93.

Shen X, Yu RK, Chen SB, Li CX, Jing Y, Zheng YJ, et al. Dermoscopy in China: Current status and future prospective. Clin Med J 2015;132:2094–104.

Song CH, Shin DS, Jang JW, Kim TL, Kim YG, Kim JS, et al. A case of livedoid vasculopathy successfully treated with sulodexide. Ann Dermatol 2020;32(6):508–11.

Tsutsui K, Shirasaki F, Takata M, Takehara K. Successful treatment of livedo vasculitis with beraprost sodium: A possible mechanism of thrombomodulin upregulation. Dermatology 1996;192(2):120–4.

Tubone MQ, Escobar GF, Peruzzo J, Schestakowsky M, Pindado N. Livedoid vasculopathy associated with peripheral neuropathy: A report of two cases. Ann Acad Med Singapore 2013;42(8):566–7.

Tuchinda P, Tammaro A, Gaspari AA. Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasmapheresis activator inhibitor–1 promoter homoygosity. Arch Dermatol 2011;147(10):1224–5.

Tuchinda P, Leentupis V, Sudrit V, Lim HW. Refractory livedoid vasculitis responding to PUVA: A report of four cases. Photodermatol Photobiol Photomed 2005;21:154–6.

Valentin FO, Tsutsui GM, Miot HA. Recrudescence of livedoid vasculopathy caused by COVID-19. Int J Dermatol 2020;59(1):e145–7.

Vasicek H, Neema S, Verma R. Livedoid vasculopathy: A review of pathogenesis and principles of management. Indian J Vener Dis 2016;2016:82;478–87.

Verma V. Livedoid vasculopathy managed with hyperbaric oxygen therapy. Med J Armed Forces India 2013;69(2):202–3.

Vieira R, Bernardes JM, Pinto JA, Costa L. Livedoid vasculopathy—A challenging disease. Acta Reumatol Port 2016;41(3):273–4.

Yang CH, Ho HC, Chan YS, Liu LB, Hong HS, Yang LC. Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen. Br J Dermatol 2013;169:474–52.

Yang CH, Shen SC, Hui RC, Huang YH, Chu PH, Ho WJ. Association between pe-
Peripheral vascular endothelial dysfunction and livedoid vasculopathy. J Am Acad Dermatol 2012;67(1):107–12.

Yong AA, Tan AW, Giam VG, Tang MB. Livedoid vasculopathy and its association with factor V Leiden mutation. Singapore Med J 2012;53(12):e258–60.

Yoshioka K, Tateishi C, Kato H, Chen KR. Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin. Clin Case Rep 2018;6(11):2045–7.

Wakelin SH, Ellis JP, Black MM. Livedoid vasculitis with anticardiolipin antibodies: Improvement with danazol. Br J Dermatol 1998;139:935–7.

Weishaupt C, Strolin A, Kahle B, Kreuter A, Schneider SW, Gerss J, et al. Anti-coagulation with rivaroxaban for livedoid vasculopathy (RILIVA): A multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016;3(2):e72–9.

Weishaupt C, Strolin A, Kahle B, Kreuter A, Schneider SW, Gerss J, et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy–A multicentre analysis. J Eur Acad Dermatol Venereol 2019;33(9):1784–91.

Wen J, Li XH, Yang QP, Yu JB. Clinical and dermoscopic features of livedoid vasculopathy. Chin Med J (Engl) 2020;33(17):2137–8.

Winchester DS, Drage LA, Davis MD. Response of livedoid vasculopathy to rivaroxaban. Br J Dermatol 2015;172(4):1148–50.

Winkelmann RK, Schroeter AL, Kierland RR, Ryan TM. Clinical studies of livedoid vasculitis (segmental hyalinizing vasculitis). Mayo Clin Proc 1974;49:746–50.

Zeni P, Finger E, Scheinberg MA. Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy. Ann Rheum Dis 2008;67:1055–6.